1. 2022-RA-1297-ESGO A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial. (20th October 2022) Authors: Oaknin, Ana; Pothuri, Bhavana; Gilbert, Lucy; Sabatier, Renaud; Brown, Jubilee; Ghamande, Sharad; Mathews, Cara; O'Malley, David M; Kristeleit, Rebecca; Boni, Valentina; Gravina, Adriano; Banerjee, Susana; Miller, Rowan E; Pikiel, Joanna; Miza, Mansoor R; Duan, Tao; Dong, Yuping; Zografos, Elefth... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 386 Patient-reported outcomes (PROS) in the garnet trial in patients (PTS) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (DMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab. (4th December 2020) Authors: Kristeleit, Rebecca; Mathews, Cara; Redondo, Andrés; Huang, Joice; Eliason, Laurie; Im, Ellie; Brown, Jubilee Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 4 Page Start: A40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. (December 2020) Authors: Subbiah, Vivek; Paz-Ares, Luis; Besse, Benjamin; Moreno, Victor; Peters, Solange; Sala, María Angeles; López-Vilariño, José Antonio; Fernández, Cristian; Kahatt, Carmen; Alfaro, Vicente; Siguero, Mariano; Zeaiter, Ali; Zaman, Khalil; López, Rafael; Ponce, Santiago; Boni, Valentina; Arrondeau, Jen... Journal: Lung cancer Issue: Volume 150(2020) Page Start: 90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Avelumab Alone or in Combination With Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study. Issue 11 (November 2021) Authors: Pujade-Lauraine, Eric; Fujiwara, Keiichi; Ledermann, Jonathan A.; Oza, Amit M.; Kristeleit, Rebecca; Ray-Coquard, Isabelle-Laure; Richardson, Gary E.; Sessa, Cristiana; Yonemori, Kan; Banerjee, Susana; Leary, Alexandra; Tinker, Anna V.; Jung, Kyung Hae; Madry, Radoslaw; Park, Sang-Yoon; Anderson,... Journal: Obstetrical & gynecological survey Issue: Volume 76:Issue 11(2021) Page Start: 673 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Avelumab Alone or in Combination With Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study. Issue 11 (November 2021) Authors: Pujade-Lauraine, Eric; Fujiwara, Keiichi; Ledermann, Jonathan A.; Oza, Amit M.; Kristeleit, Rebecca; Ray-Coquard, Isabelle-Laure; Richardson, Gary E.; Sessa, Cristiana; Yonemori, Kan; Banerjee, Susana; Leary, Alexandra; Tinker, Anna V.; Jung, Kyung Hae; Madry, Radoslaw; Park, Sang-Yoon; Anderson,... Journal: Obstetrical & gynecological survey Issue: Volume 76:Issue 11(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Issue 7 (July 2021) Authors: Pujade-Lauraine, Eric; Fujiwara, Keiichi; Ledermann, Jonathan A; Oza, Amit M; Kristeleit, Rebecca; Ray-Coquard, Isabelle-Laure; Richardson, Gary E; Sessa, Cristiana; Yonemori, Kan; Banerjee, Susana; Leary, Alexandra; Tinker, Anna V; Jung, Kyung Hae; Madry, Radoslaw; Park, Sang-Yoon; Anderson, Cha... Journal: Lancet oncology Issue: Volume 22:Issue 7(2021) Page Start: 1034 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. (May 2017) Authors: George, Angela; Kristeleit, Rebecca; Rafii, Saeed; Michie, Caroline O.; Bowen, Rebecca; Michalarea, Vasiliki; van Hagen, Tom; Wong, Mabel; Rallis, Grigorios; Molife, L. Rhoda; Lopez, Juanita; Banerji, Udai; Banerjee, Susana N.; Gore, Martin E.; de Bono, Johann S.; Kaye, Stan B.; Yap, Timothy A. Journal: European journal of cancer Issue: Volume 76(2017) Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study. Issue 11 (5th November 2021) Authors: Kristeleit, Rebecca; Moreno, Victor; Boni, Valentina; Guerra, Eva M; Kahatt, Carmen; Romero, Ignacio; Calvo, Emiliano; Basté, Neus; López-Vilariño, José A; Siguero, Mariano; Alfaro, Vicente; Zeaiter, Ali; Forster, Martin Journal: International journal of gynecological cancer Issue: Volume 31:Issue 11(2021) Page Start: 1428 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study. Issue 11 (5th October 2021) Authors: Kristeleit, Rebecca; Moreno, Victor; Boni, Valentina; Guerra, Eva M; Kahatt, Carmen; Romero, Ignacio; Calvo, Emiliano; Basté, Neus; López-Vilariño, José A; Siguero, Mariano; Alfaro, Vicente; Zeaiter, Ali; Forster, Martin Journal: International journal of gynecological cancer Issue: Volume 31:Issue 11(2021) Page Start: 1428 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. (January 2017) Authors: Marth, Christian; Vergote, Ignace; Scambia, Giovanni; Oberaigner, Willi; Clamp, Andrew; Berger, Regina; Kurzeder, Christian; Colombo, Nicoletta; Vuylsteke, Peter; Lorusso, Domenica; Hall, Marcia; Renard, Vincent; Pignata, Sandro; Kristeleit, Rebecca; Altintas, Sevilay; Rustin, Gordon; Wenham, Rob... Journal: European journal of cancer Issue: Volume 70(2017) Page Start: 111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗